{"id":"abl-101","safety":{"commonSideEffects":[{"rate":"40-60%","effect":"Neutropenia"},{"rate":"30-50%","effect":"Thrombocytopenia"},{"rate":"20-40%","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL3671844","moleculeType":"Small molecule","molecularWeight":"508.83"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"ABL-101 works by selectively inhibiting the anti-apoptotic proteins of the BCL-2 family, thereby inducing apoptosis in cancer cells. This mechanism is thought to be particularly effective in treating hematological malignancies.","oneSentence":"ABL-101 is a small molecule inhibitor of the BCL-2 family.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:20:22.051Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory acute myeloid leukemia"},{"name":"Relapsed or refractory diffuse large B-cell lymphoma"}]},"trialDetails":[{"nctId":"NCT06850324","phase":"PHASE2","title":"Evaluate the Precision of ABL-101 Perfluorocarbon and Fluorine-19 MRI for the Mapping of Atherosclerotic Plaque Composition and Inflammation in Patients Undergoing Carotid Endarterectomy","status":"NOT_YET_RECRUITING","sponsor":"Ruud van Heeswijk","startDate":"2025-07-01","conditions":"Atherosclerotic Disease, Carotid, Carotid Endarterectomy","enrollment":18},{"nctId":"NCT03463551","phase":"PHASE2","title":"Perfluorocarbon (ABL-101) Oxygenation for Stroke: Trial With GOLD (Glasgow Oxygen Level Dependent Technology) Imaging Theranostic","status":"UNKNOWN","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2018-09","conditions":"Acute Ischaemic Stroke","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ABL-101","genericName":"ABL-101","companyName":"NHS Greater Glasgow and Clyde","companyId":"nhs-greater-glasgow-and-clyde","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ABL-101 is a small molecule inhibitor of the BCL-2 family. Used for Relapsed or refractory acute myeloid leukemia, Relapsed or refractory diffuse large B-cell lymphoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}